Back to top
more

InMode (INMD)

(Delayed Data from NSDQ)

$14.07 USD

14.07
1,363,925

+0.33 (2.40%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $14.07 0.00 (0.00%) 5:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Syneos Health (SYNH) New Partnership to Enhance Clinical Trials

by Zacks Equity Research

Syneos Health (SYNH) new partnership will extend the company's mission to boost research and enable universal patient and provider access with clinical research services.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Quest Diagnostics, LabCorp, InMode, Bioanalytical Systems and Semler Scientific

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Quest Diagnostics, LabCorp, InMode, Bioanalytical Systems and Semler Scientific

Urmimala Biswas headshot

Fed Eyes Faster Recovery in 2021: 3 MedTech Stocks to Buy

by Urmimala Biswas

MedTech stocks like INMD, BASI and SMLR are expected to maintain market-beating momentum in 2021.

Zacks Equity Research

Will InMode (INMD) Gain on Rising Earnings Estimates?

by Zacks Equity Research

InMode (INMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

InMode (INMD) Moves 6% Higher: Will This Strength Last?

by Zacks Equity Research

InMode (INMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

InMode (INMD) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have contributed to the company's Q4 top line.

Zacks Equity Research

Zacks.com featured highlights include: Azure Power Global, Mueller Industries, H&E Equipment Services, Korea Electric Power and InMode

by Zacks Equity Research

Zacks.com featured highlights include: Azure Power Global, Mueller Industries, H&E Equipment Services, Korea Electric Power and InMode

Zacks Equity Research

Stryker (SYK) Buys OrthoSensor to Grow in Sensor Technology

by Zacks Equity Research

Stryker's (SYK) acquisition of OrthoSensor will help surgeons with real-time data-driven solutions and improve patient outcomes.

Nalak Das headshot

5 Stocks With Recent Price Strength to Tap Market Rally

by Nalak Das

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Zacks Equity Research

Exagen (XGN) Looks Good: Stock Adds 9.3% in Session

by Zacks Equity Research

Exagen (XGN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Zacks Equity Research

Medtronic (MDT) MITG Shows Fast Recovery Amid COVID-19 Woes

by Zacks Equity Research

Medtronic (MDT) expects fiscal third-quarter MITG growth to be in the low single digits.

Zacks Equity Research

Zacks.com featured highlights include: MCRI, FCAU, PIPR, NPO and INMD

by Zacks Equity Research

Zacks.com featured highlights include: MCRI, FCAU, PIPR, NPO and INMD

Nalak Das headshot

5 Stocks With Recent Price Strength as Indexes Hit Record High

by Nalak Das

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Zacks Equity Research

Is InMode (INMD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (INMD) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

HEXO Catches Eye: Stock Jumps 9.4%

by Zacks Equity Research

HEXO saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Zacks Equity Research

Agios' (AGIO) Phase III Study on Mitapivat Meets Primary Goal

by Zacks Equity Research

Agios' (AGIO) phase III ACTIVATE study evaluating mitapivat for addressing PK deficiency in patients with no regular blood transfusions achieves the primary goal.

Zacks Equity Research

Surging Earnings Estimates Signal Upside for InMode (INMD) Stock

by Zacks Equity Research

InMode (INMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Is InMode (INMD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (INMD) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Zacks.com featured highlights include: Catalyst Biosciences, UFP Industries, VeriSign, InMode and Castle Biosciences

by Zacks Equity Research

Zacks.com featured highlights include: Catalyst Biosciences, UFP Industries, VeriSign, InMode and Castle Biosciences

Shrabana Mukherjee headshot

5 Stocks Set to Pop on New Analyst Coverage

by Shrabana Mukherjee

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Catalyst Biosciences (CBIO), UFP Industries (UFPI), VeriSign (VRSN), InMode (INMD) and Castle Biosciences (CSTL).

Tracey Ryniec headshot

Stock Investors: What's the Next Hot Industry?

by Tracey Ryniec

Technology won't always be on top. There's a bunch of budding industries that could prove to be winners over the next 5 years.

Benjamin Rains headshot

Find Strong Stocks with this New Analyst Coverage Screener

by Benjamin Rains

We screened for strong stocks that recently received new analyst coverage, as we enter the heart of Q3 earnings season...

Zacks Equity Research

Zacks.com featured highlights include: Perion Network, Live Oak Bancshares, LexinFintech and InMode

by Zacks Equity Research

Zacks.com featured highlights include: Perion Network, Live Oak Bancshares, LexinFintech and InMode

Shrabana Mukherjee headshot

4 Stocks in Focus on New Analyst Coverage

by Shrabana Mukherjee

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Perion (PERI), Live Oak (LOB), LexinFintech (LX) and InMode (INMD).

Zacks Equity Research

Moving Average Crossover Alert: InMode

by Zacks Equity Research

InMode is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.